AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
Keeton, Erika K., McEachern, Kristen, Dillman, Keith S., Palakurthi, Sangeetha, Cao, Yichen, Grondine, Michael R., Kaur, Surinder, Wang, Suping, Chen, Yuching, Wu, Allan, Shen, Minhui, Gibbons, Francis D., Lamb, Michelle L., Zheng, Xiaolan, Stone, Richard M., DeAngelo, Daniel J., Platanias, Leonidas C., Dakin, Les A., Chen, Huawei, Lyne, Paul D., Huszar, Dennis
Published in Blood (06.02.2014)
Published in Blood (06.02.2014)
Get full text
Journal Article
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases
Dakin, Les A., Block, Michael H., Chen, Huawei, Code, Erin, Dowling, James E., Feng, Xiaomei, Ferguson, Andrew D., Green, Isabelle, Hird, Alexander W., Howard, Tina, Keeton, Erika K., Lamb, Michelle L., Lyne, Paul D., Pollard, Hannah, Read, Jon, Wu, Allan J., Zhang, Tao, Zheng, Xiaolan
Published in Bioorganic & medicinal chemistry letters (15.07.2012)
Published in Bioorganic & medicinal chemistry letters (15.07.2012)
Get full text
Journal Article
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
Hardesty, Melissa M., Krivak, Thomas C., Wright, Gail S., Hamilton, Erika, Fleming, Evelyn L., Belotte, Jimmy, Keeton, Erika K., Wang, Ping, Gupta, Divya, Clements, Aine, Gray, Heidi J., Konecny, Gottfried E., Moore, Richard G., Richardson, Debra L.
Published in Gynecologic oncology (01.08.2022)
Published in Gynecologic oncology (01.08.2022)
Get full text
Journal Article
PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer
Kirschner, Austin N, Wang, Jie, van der Meer, Riet, Anderson, Philip D, Franco-Coronel, Omar E, Kushner, Max H, Everett, Joel H, Hameed, Omar, Keeton, Erika K, Ahdesmaki, Miika, Grosskurth, Shaun E, Huszar, Dennis, Abdulkadir, Sarki A
Published in JNCI : Journal of the National Cancer Institute (01.02.2015)
Published in JNCI : Journal of the National Cancer Institute (01.02.2015)
Get full text
Journal Article
Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208
Tron, Adriana E., Keeton, Erika K., Ye, Minwei, Casas-Selves, Matias, Chen, Huawei, Dillman, Keith S., Gale, Rosemary E., Stengel, Chloe, Zinda, Michael, Linch, David C., Lai, Zhongwu, Khwaja, Asim, Huszar, Dennis
Published in Leukemia & lymphoma (01.12.2016)
Published in Leukemia & lymphoma (01.12.2016)
Get full text
Journal Article
32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
Werner, Theresa L., Lakhani, Nehal, Edenfield, William, Hays, John, Zarwan, Corrine, Buscema, Joseph, Burns, Timothy, Carrington, Cassandra, Keeton, Erika K., Burger, Robert A., Anderson, Charles
Published in Gynecologic oncology reports (01.12.2022)
Published in Gynecologic oncology reports (01.12.2022)
Get full text
Journal Article
Abstract 2353: Novel inhibitors of PIM-1, PIM-2, and PIM-3 protein kinases: medicinal chemistry leading to AZD1208
Lamb, Michelle L., Dakin, Les A., Block, Michael H., Chen, Huawei, Code, Erin, Dowling, James E., Feng, Xiaomei, Ferguson, Andrew D., Green, Isabelle, Hird, Alexander W., Howard, Tina, Huszar, Dennis, Keeton, Erika K., Lyne, Paul D., Pollard, Hannah, Rooney, Michael, Read, Jon, Wu, Allan J., Zhang, Tao, Zheng, Xiaolan
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article